Landlocked developing countries (LLDCs) vs Uruguay: Proportion of the target population who received a 3rd dose
Landlocked developing countries (LLDCs)
76.0%
in 2024
Uruguay
96.0%
in 2024
Landlocked developing countries (LLDCs) rank
17th
Uruguay rank
16th
Proportion of the target population who received a 3rd dose over time
- Landlocked developing countries (LLDCs)
- Uruguay
How they compare
Uruguay currently reports 96.0% against 76.0% in Landlocked developing countries (LLDCs), a difference of 20.0%.
That makes Uruguay's figure about 1.3 times Landlocked developing countries (LLDCs)'s.
Across all 15 years both countries report, Uruguay has been ahead every year.
Landlocked developing countries (LLDCs) ranks 17th and Uruguay ranks 16th of 36 groups.
Uruguay has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Landlocked developing countries (LLDCs) | Uruguay | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 44.0% | 93.4% | 49.4% | Uruguay |
| 2020s | 72.2% | 94.4% | 22.2% | Uruguay |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher proportion of the target population who received a 3rd dose of, Landlocked developing countries (LLDCs) or Uruguay?
- Uruguay, at 96.0% against 76.0% in Landlocked developing countries (LLDCs) as of 2024.
- What is the difference in proportion of the target population who received a 3rd dose of between Landlocked developing countries (LLDCs) and Uruguay?
- 20.0%, with Uruguay ahead.
- How many years of comparable data are there for Landlocked developing countries (LLDCs) and Uruguay?
- 15 years are reported by both, from 2010 to 2024.
- How do Landlocked developing countries (LLDCs) and Uruguay rank globally for proportion of the target population who received a 3rd dose of?
- Landlocked developing countries (LLDCs) ranks 17th and Uruguay ranks 16th of 36 groups.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Proportion of the target population who received a 3rd dose of pneumococcal conjugate (PCV3) vaccine (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.